Without a recovery plan, the Italian pharmaceutical industry is destined to disappear. This is claimed by the president of Farmindustria, Massimo Scaccabarozzi, calling into question the constant decline of the internal market - minus 3.3% in 2012 - but above all the overall conditions of competitiveness in Italy, where companies work with ballast around their necks and day by day they ask themselves: "Why not relocate?". Over the last few years of crisis, the many multinationals historically based with factories and laboratories in the areas around Rome and Milan answered the question first. And in fact, many of them have chosen to lighten their presence and risk in Italy, reducing plants and employees. Among the giants appearing in the Confindustria lists, it is enough to mention, for example, Bayer, Gsk, Roche, Aptuit, Sanofi, Dompè. Here, compared to the current 65,000 employees surveyed in the sector (90% of whom with a degree), the statistics show that there were 10,000 more in 2008. All this in an industry that, thanks also to Big Pharma, exports 61% of its production and which invests 2.4 billion euros every year, about half of which in research. (p.pos.)
June 24, 2013 – 
